dc.date.accessioned | 2018-08-03T11:46:46Z | |
dc.date.available | 2019-02-15T23:31:33Z | |
dc.date.created | 2018-01-29T09:05:49Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Urbanucci, Alfonso Mills, Ian Geoffrey . Bromodomain-containing proteins in prostate cancer. Molecular and Cellular Endocrinology. 2017, 17, 30334-9-30339 | |
dc.identifier.uri | http://hdl.handle.net/10852/62704 | |
dc.description.abstract | Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin. Bromodomain (BRD)-containing proteins fall into the latter category and significant progress has been made in developing small molecule inhibitors that target a particular subgroup of BRD-containing proteins known as the Bromodomain and extra-terminal (BET) family proteins. These inhibitors have proven particularly effective in inactivating c-Myc in lymphoma but more recently members of the BET family have also been identified as AR-interacting proteins raising the prospect of using these inhibitors as an alternative strategy for targeting AR-driven cancers. In this review we will provide an overview of BRD-containing proteins and the potential for exploiting them as biomarkers and drug targets in prostate cancer. | en_US |
dc.language | EN | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science | |
dc.title | Bromodomain-containing proteins in prostate cancer | en_US |
dc.type | Journal article | en_US |
dc.creator.author | Urbanucci, Alfonso | |
dc.creator.author | Mills, Ian Geoffrey | |
cristin.unitcode | 185,57,0,0 | |
cristin.unitname | Norsk Senter for Molekylærmedisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | preprint | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1553922 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Molecular and Cellular Endocrinology&rft.volume=17&rft.spage=30334-9&rft.date=2017 | |
dc.identifier.jtitle | Molecular and Cellular Endocrinology | |
dc.identifier.volume | 462 | |
dc.identifier.startpage | 31 | |
dc.identifier.endpage | 40 | |
dc.identifier.doi | http://dx.doi.org/10.1016/j.mce.2017.06.007 | |
dc.identifier.urn | URN:NBN:no-65277 | |
dc.type.document | Tidsskriftartikkel | en_US |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0303-7207 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/62704/2/MCE-D-16-00643R1.pdf | |
dc.type.version | AcceptedVersion | |